Get startedLog in
    Picture of Pardes Biosciences logo

    PRDS — Pardes Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall Cap
    All News

    Brief: Pardes Biosciences Announces Commencement Of Phase 2 Trial Evaluating PBI-0451 For The Treatment Of SARS-CoV-2 Infections

    Picture of Pardes Biosciences logoPardes Biosciences
    13/09/2022 15:03
    Sept 13 (Reuters) - Pardes Biosciences Inc  PRDS.O :
    * PARDES BIOSCIENCES ANNOUNCES COMMENCEMENT OF PHASE 2 TRIAL
EVALUATING PBI-0451 FOR THE TREATMENT OF SARS-COV-2 INFECTIONS
    * PARDES BIOSCIENCES ANNOUNCES COMMENCEMENT OF PHASE 2 TRIAL
EVALUATING PBI-0451 FOR THE TREATMENT OF SARS-COV-2 INFECTIONS
    * PARDES - PHASE 2 TRIAL EXPECTED TO ENROLL 210 PATIENTS AT
ABOUT
75 SITES TO EVALUATE ANTIVIRAL ACTIVITY, SAFETY, & EFFICACY OF
PBI-0451 VERSUS PLACEBO
    * PARDES BIOSCIENCES INC - INTERIM DATA FROM PHASE 2
ANTICIPATED
IN Q1 2023

Source text for Eikon:  ID:nGNX5b19cl 
Further company coverage:  PRDS.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Pardes Biosciences

    See all news